CRM1

CRM1 Products

All (7)
CRM1 Inhibitors (7)
New CRM1 Products

Catalog No.	Product Name	Information	Product Use Citations
S7252	Selinexor (KPT-330)	Selinexor (KPT-330, ATG-010) is an orally bioavailable selective CRM1 inhibitor. Phase 2.	Gastroenterology, 2024, S0016-5085(24)00062-3 Nat Cell Biol, 2024, 10.1038/s41556-023-01338-y Nat Commun, 2024, 15(1):2859
S7551	Piperlongumine	Piperlongumine (PPLGM, Piplartine), a natural alkaloid from Piper longum L., increases the level of reactive oxygen species (ROS) and selectively kills cancer cells. It is a direct TrxR1 inhibitor with suppressive activity against gastric cancer and a novel inhibitor of CRM1; also an inhibitor of PI3K/Akt/mTOR in human breast cancer cells.	J Oral Biosci, 2024, S1349-0079(24)00071-9 J Exp Clin Cancer Res, 2023, 42(1):118 Drug Des Devel Ther, 2023, 17:1387-1394
S8397	Eltanexor (KPT-8602)	Eltanexor (KPT-8602, ONO-7706，ATG-016) is a second-generation, orally bioavailable XPO1 (also known as CRM1) inhibitor with IC50 values of 20−211 nM in 10 AML lines after 3 days exposure.	Gastroenterology, 2024, S0016-5085(24)00062-3 Cells, 2024, 13(7)632 Sci Rep, 2023, 13(1):18554
S7125	KPT-185	KPT-185 is a selective CRM1 inhibitor that induces growth inhibition and apoptosis in a panel of NHL cell lines with a median IC50 ~25 nM.	Cell Chem Biol, 2022, S2451-9456(22)00275-6 Oncotarget, 2020, 11(36):3371-3386 EMBO Rep, 2019, 20(11):e48150
S7707	Verdinexor (KPT-335)	Verdinexor (KPT-335, ATG-527) is an orally bioavailable, selective XPO1/CRM1 inhibitor.	J Biomed Sci, 2022, 29(1):44 Cell Rep, 2022, 38(10):110472 NAR Cancer, 2022, 4(4):zcac033
S7251	KPT-276	KPT-276 is an orally bioavailable selective CRM1 inhibitor.	Elife, 2021, 10e67587 Front Oncol, 2020, 10:1424 Nat Commun, 2019, 10(1):3827
S7580	Leptomycin B	Leptomycin B (LMB, CI 940, Elactocin, Mantuamycin, NSC 364372) is a potent antifungal antibiotic isolated from Streptomyces and acts as a specific inhibitor of the nuclear export factor CRM1. Leptomycin B rapidly induces cytotoxic effects in cancer cell lines via covalent inhibition of CRM1 with IC50 values of 0.1 nM–10 nM.	Cell Death Discov, 2023, 9(1):324 Cell Death Discov, 2023, 9(1):324 Commun Biol, 2022, 5(1):1391
S7252	Selinexor (KPT-330)	Selinexor (KPT-330, ATG-010) is an orally bioavailable selective CRM1 inhibitor. Phase 2.	Gastroenterology, 2024, S0016-5085(24)00062-3 Nat Cell Biol, 2024, 10.1038/s41556-023-01338-y Nat Commun, 2024, 15(1):2859
S7551	Piperlongumine	Piperlongumine (PPLGM, Piplartine), a natural alkaloid from Piper longum L., increases the level of reactive oxygen species (ROS) and selectively kills cancer cells. It is a direct TrxR1 inhibitor with suppressive activity against gastric cancer and a novel inhibitor of CRM1; also an inhibitor of PI3K/Akt/mTOR in human breast cancer cells.	J Oral Biosci, 2024, S1349-0079(24)00071-9 J Exp Clin Cancer Res, 2023, 42(1):118 Drug Des Devel Ther, 2023, 17:1387-1394
S8397	Eltanexor (KPT-8602)	Eltanexor (KPT-8602, ONO-7706，ATG-016) is a second-generation, orally bioavailable XPO1 (also known as CRM1) inhibitor with IC50 values of 20−211 nM in 10 AML lines after 3 days exposure.	Gastroenterology, 2024, S0016-5085(24)00062-3 Cells, 2024, 13(7)632 Sci Rep, 2023, 13(1):18554
S7125	KPT-185	KPT-185 is a selective CRM1 inhibitor that induces growth inhibition and apoptosis in a panel of NHL cell lines with a median IC50 ~25 nM.	Cell Chem Biol, 2022, S2451-9456(22)00275-6 Oncotarget, 2020, 11(36):3371-3386 EMBO Rep, 2019, 20(11):e48150
S7707	Verdinexor (KPT-335)	Verdinexor (KPT-335, ATG-527) is an orally bioavailable, selective XPO1/CRM1 inhibitor.	J Biomed Sci, 2022, 29(1):44 Cell Rep, 2022, 38(10):110472 NAR Cancer, 2022, 4(4):zcac033
S7251	KPT-276	KPT-276 is an orally bioavailable selective CRM1 inhibitor.	Elife, 2021, 10e67587 Front Oncol, 2020, 10:1424 Nat Commun, 2019, 10(1):3827
S7580	Leptomycin B	Leptomycin B (LMB, CI 940, Elactocin, Mantuamycin, NSC 364372) is a potent antifungal antibiotic isolated from Streptomyces and acts as a specific inhibitor of the nuclear export factor CRM1. Leptomycin B rapidly induces cytotoxic effects in cancer cell lines via covalent inhibition of CRM1 with IC50 values of 0.1 nM–10 nM.	Cell Death Discov, 2023, 9(1):324 Cell Death Discov, 2023, 9(1):324 Commun Biol, 2022, 5(1):1391

Choose Selective CRM1 Inhibitors